ValuEngine upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a strong sell rating to a sell rating in a research report report published on Monday, April 9th.
A number of other research firms have also weighed in on LJPC. BidaskClub raised shares of La Jolla Pharmaceutical from a hold rating to a buy rating in a report on Friday, February 9th. Jefferies Group cut shares of La Jolla Pharmaceutical from a buy rating to an underperform rating and cut their price target for the stock from $40.00 to $29.00 in a research note on Monday, February 12th. Chardan Capital boosted their price target on shares of La Jolla Pharmaceutical from $90.00 to $100.00 and gave the stock a buy rating in a research note on Thursday, January 25th. Zacks Investment Research cut shares of La Jolla Pharmaceutical from a hold rating to a sell rating in a research note on Thursday, February 15th. Finally, HC Wainwright boosted their price target on shares of La Jolla Pharmaceutical from $62.00 to $91.00 and gave the stock a buy rating in a research note on Friday, December 29th. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $55.86.
La Jolla Pharmaceutical stock traded down $0.01 during midday trading on Monday, reaching $31.01. 172,528 shares of the stock were exchanged, compared to its average volume of 548,453. The firm has a market capitalization of $808.92, a PE ratio of -5.73 and a beta of 1.36. La Jolla Pharmaceutical has a 52 week low of $22.68 and a 52 week high of $41.36.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.49). research analysts anticipate that La Jolla Pharmaceutical will post -4.94 earnings per share for the current year.
In other La Jolla Pharmaceutical news, Director Kevin C. Tang acquired 508,474 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was bought at an average price of $29.50 per share, with a total value of $14,999,983.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive acquired 175,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The stock was acquired at an average cost of $32.72 per share, with a total value of $5,726,000.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 1,544,474 shares of company stock valued at $46,485,863. Corporate insiders own 25.47% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC purchased a new stake in shares of La Jolla Pharmaceutical in the 4th quarter valued at $276,000. LPL Financial LLC purchased a new stake in shares of La Jolla Pharmaceutical in the 4th quarter valued at $434,000. Perceptive Advisors LLC boosted its stake in shares of La Jolla Pharmaceutical by 57.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,388,611 shares of the biopharmaceutical company’s stock valued at $109,046,000 after purchasing an additional 1,231,600 shares in the last quarter. Jafra Capital Management LP boosted its stake in shares of La Jolla Pharmaceutical by 238.5% in the 4th quarter. Jafra Capital Management LP now owns 30,000 shares of the biopharmaceutical company’s stock valued at $965,000 after purchasing an additional 21,137 shares in the last quarter. Finally, Consonance Capital Management LP boosted its stake in shares of La Jolla Pharmaceutical by 3.8% in the 4th quarter. Consonance Capital Management LP now owns 2,079,311 shares of the biopharmaceutical company’s stock valued at $66,912,000 after purchasing an additional 76,792 shares in the last quarter. 96.29% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “La Jolla Pharmaceutical (NASDAQ:LJPC) Stock Rating Upgraded by ValuEngine” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://ledgergazette.com/2018/04/17/la-jolla-pharmaceutical-ljpc-upgraded-to-sell-at-valuengine.html.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.